Metabolex takes $8.6M to treat diabetes
Metabolex, maker of treatments for Type 2 diabetes, has raised $8.6 million in a fifth round of funding to fund trials on its newest product. Based in Hayward, Calif., the company is backed by Alta Partners, Bay City Capital, Birchmere Ventures, Charter Ventures, Merlin Biomed, Novo Ventures, Next Chapter Holdings, VantagePoint Venture Partners, Venrock and Versant Ventures.
Next Story: Tethys picks up $25M for diabetes diagnostic
Previous Story: Shazam, the song-recognition app, launches $4.99 version with more features
About the Author, Camille Ricketts
Camille was the lead writer for GreenBeat until August 2010. To reach VentureBeat's current writers, email tips@venturebeat.com.
